Bibliografische notaFunding Information:
HW's institution (Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium) received financial compensation for advisory board and lecture fees from AbbVie, ARIEZ, AstraZeneca, AstraZeneca Ireland, Biocartes, Congress Care, Daiichi Sankyo, Eisai, Immutep, Federaal Kenniscentrum Voor de Gezondheidszorg, Lilly, Merck Sharp & Dohme, Novartis, ORION Corporation, Pfizer, PSI CRO AG, Puma Biotech, Roche, Sirtex, The Planning Shop, and Aptitude Health; and an unrestricted research grant from Roche. LD's institution received research grants from Boehringer Ingelheim; financial compensation for advisory board and lecture fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, and Roche; and travel support from AstraZeneca, Merck Sharp & Dohme, and Roche. FB received financial compensation for advisory boards and lecture fees from Bayer, Bristol Myers Squibb, GlaxoSmithKline, Merck, and Merck Sharp & Dohme; a research grant from Sanofi; and travel support from Bristol Myers Squibb, GlaxoSmithKline, and Merck Sharp & Dohme. All other authors declare no competing interests.
HW is a recipient of the Fonds voor Wetenschappelijk Onderzoek – Vlaanderen (funds from The Research Foundation – Flanders).
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
Copyright 2022 Elsevier B.V., All rights reserved.
- CELL LUNG-CANCER